Common goal: More powerful immunotherapies against cancer

Mainz, August 10, 2018 – The new Helmholtz Institute “HI-TRON Mainz” aims to develop effective immunotherapies and identify new biomarkers for cancer treatments. HI-TRON is a collaboration between the German Cancer Research Center (DKFZ) and the research institute TRON – Translational Oncology at the University Medical Center of Johannes Gutenberg University Mainz. Cooperation agreements have

Continue Reading

Challenges towards the realization of individualized cancer vaccines

Mainz, August 10, 2018 – TRON is delighted to announce a Comment authored by Özlem Türeci and Ugur Sahin in the journal Nature Biomedical Engineering. “Challenges towards the realization of individualized cancer vaccines” discusses the challenges of optimizing vaccine design, manufacturing and affordability, and identifying the most suitable clinical setting(s). TRON colleagues Martin Löwer, Barbara

Continue Reading

TRON enters into a research collaboration with Astellas Pharma Inc., Japan

Mainz – TRON (Translational Oncology at the University Medical Center of the Johannes Gutenberg-University Mainz), a non-profit organization and internationally recognized leader in tumor immunology and cancer therapy research, has entered into a research collaboration with Astellas Pharma Inc., a company dedicated to improving the health of people through the provision of innovative and reliable

Continue Reading

OVERCOMING THE INNATE RESISTANCE OF CANCER TO THERAPY

Trento, Italy, June 26, 2018 – Currently, oncologists and cancer scientists face an abiding problem of major proportion, namely the emergence of resistance of certain cancers-some very common- to any therapy during their course. For some of these tumors, such as melanoma and kidney cancer, immune therapy has shown remarkable effects, but only a small

Continue Reading

Krebstherapien maßgeschneidert für jeden Patienten

Mainz, 17. Mai 2018 – Jeder Tumor ist anders. “Krebs entsteht durch individuelle Mutationen”, erklärt Prof. Dr. Ugur Sahin. “Wenn wir uns zum Beispiel den Lungenkrebs verschiedener Patienten anschauen, dann sind diese sehr unterschiedlich. Sie haben im Durchschnitt weniger als fünf Prozent der Mutationen gemeinsam, 95 Prozent sind ganz individuell. Herkömmliche Therapieansätze konzentrieren sich auf

Continue Reading

Biomedical Informatics Symposium

Mainz, June 20, 2018 – Computational Analysis becomes ever more important for the advancement of personalized medicine. Bioinformatics accelerate the patient-centric molecular characterization of diseases and lead to a deeper understanding of the underlying mechanisms thus facilitating the development of novel drugs. Progress in Artificial Intelligence has a strong impact on clinical decision making in

Continue Reading

The Evolution of RNA-based Cancer Vaccines

Ghent, Belgium, May 25, 2018 – VIB conference series hosts the MEDICAL BIOTECHNOLOGY focus meeting May 24-25, 2018, in Ghent Belgium. The conference features talks on new disruptive technologies for early diagnosis and more effective therapeutic intervention in established chronic diseases. Dr. Mustafa Diken will share years of experience in his talk “The evolution of

Continue Reading

CIMT 2018 Annual Meeting

Mainz, May 15-17, 2018 – CIMT 2018 Annual Meeting We are excited about the upcoming Annual Meeting of the Association for Cancer Immunotherapy (CIMT) in our hometown Mainz. Our scientists will be presenting their research in several sessions and look forward to discussing their projects. Thursday, 17 May 2018, Short Talk Session IV Therapeutic Vaccination

Continue Reading

Prof. Ugur Sahin receives prestigious European Research Council (ERC) Advanced Grant for personalized cancer vaccines

Mainz, Germany, April 18, 2018 – Ugur Sahin, Scientific Director at TRON, has been awarded one of the prestigious ERC Advanced Grants 2017 for his project ‘SUMMIT – Stepping Up mRNA Mutanome Immunotherapy’, totaling 2.5 Million Euros over 5 years. The ERC Advanced Grants are awarded to well-established, leading principal investigators to pursue ground-breaking projects. SUMMIT is one

Continue Reading

Three-year research grant to develop new treatment approaches for neuroendocrine tumors

We are pleased to announce a three-year grant from the Falconwood Foundation, New York, USA, totalling 3 Million Euros. The grant supports the launch of a new research project to identify biomarkers specific for neuroendocrine tumors (NETs) that are crucial for the development of new, personalized immunotherapies to treat NET patients. Further details are announced

Continue Reading